Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

被引:1071
作者
Marr, KA
Carter, RA
Crippa, F
Wald, A
Corey, L
机构
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA
[2] Univ Washington, Dept Med, Seattle, WA 98109 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98109 USA
[4] Univ Washington, Dept Lab Med, Seattle, WA 98109 USA
关键词
D O I
10.1086/339202
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Reports have focused on the emergence of moulds as pathogens in recipients of hematopoietic stem cell transplants. To review the incidence of and risks for mould infections, we examined the records of 5589 patients who underwent hematopoietic stem cell transplantation at the Fred Hutchinson Cancer Research Center (Seattle) from 1985 through 1999. After 1992, the incidence of invasive aspergillosis increased in allograft recipients and remained high through the 1990s. Infections with non-fumigatus Aspergillus species, Fusarium species, and Zygomycetes increased during the late 1990s, especially in patients who received multiple transplants. Although infection caused by Scedosporium species was common in patients who had neutropenia, infection caused by Zygomycetes typically occurred later after transplantation, when patients had graft-versus-host disease. The overall 1-year survival rate was equally poor (20%) for all patients with mould infections. The results of the present study demonstrate the changing epidemiology of mould infections, emphasizing the increasing importance of amphotericin B-resistant organisms and the differences in risks and outcome of infection with different filamentous fungi.
引用
收藏
页码:909 / 917
页数:9
相关论文
共 29 条
[1]  
ALANGADEN G, 1994, BONE MARROW TRANSPL, V14, P919
[2]   Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[3]   Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome [J].
Bensinger, WI ;
Buckner, CD ;
Anasetti, C ;
Clift, R ;
Storb, R ;
Barnett, T ;
Chauncey, T ;
Shulman, H ;
Appelbaum, FR .
BLOOD, 1996, 88 (07) :2787-2793
[4]   Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].
Boutati, EI ;
Anaissie, EJ .
BLOOD, 1997, 90 (03) :999-1008
[5]   MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - A RANDOMIZED STUDY COMPARING CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION WITH BUSULFAN AND CYCLOPHOSPHAMIDE [J].
CLIFT, RA ;
BUCKNER, CD ;
THOMAS, ED ;
BENSINGER, WI ;
BOWDEN, R ;
BRYANT, E ;
DEEG, HJ ;
DONEY, KC ;
FISHER, LD ;
HANSEN, JA ;
MARTIN, P ;
MCDONALD, GB ;
SANDERS, JE ;
SCHOCH, G ;
SINGER, J ;
STORB, R ;
SULLIVAN, KM ;
WITHERSPOON, RP ;
APPELBAUM, FR .
BLOOD, 1994, 84 (06) :2036-2043
[6]  
CRIPPA F, 2002, IN PRESS BIOL BLOOD
[7]   Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection [J].
Denning, DW ;
Radford, SA ;
Oakley, KL ;
Hall, L ;
Johnson, EM ;
Warnock, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :401-414
[8]   An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome [J].
Denning, DW ;
Marinus, A ;
Cohen, J ;
Spence, D ;
Herbrecht, R ;
Pagano, L ;
Kibbler, C ;
Kcrmery, V ;
Offner, F ;
Cordonnier, C ;
Jehn, U ;
Ellis, M ;
Collette, L ;
Sylvester, R .
JOURNAL OF INFECTION, 1998, 37 (02) :173-180
[9]  
DRAKOS PE, 1993, BONE MARROW TRANSPL, V12, P203
[10]  
Fisher L.D., 1993, BIOSTATISTICS METHOD